Osteoporosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had a hip (femoral neck) fracture that likely happened due to osteoporosis — meaning it occurred with little or no significant injury — and who are being treated with a hip replacement surgery.
- People who are mentally able to understand the study and have signed a consent form agreeing to take part.
Who may not be able to join:
- People who have had previous bone fractures related to osteoporosis.
- People who have previously had prosthetic (replacement) joint surgery for a bone or joint condition.
- People who already had a condition before the fracture that meant they could not move around and were permanently immobile.
- People with a cancer diagnosis.
- People with an autoimmune disease (where the immune system attacks the body).
- People with severe muscle diseases.
- People with long-term (chronic) viral infections, including hepatitis B, hepatitis C, or HIV.
- People who are currently on long-term medication for osteoporosis, immune-suppressing conditions, or who regularly use insulin.
- People with Paget's disease (a condition affecting how bones are rebuilt and repaired).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nicola Baldini, M.D., University of Bologna, Istituto Ortopedico Rizzoli
Phone: +39 0516366748
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Acceptability of the SARC-F questionnaire; Frequency of positive SARC-F questionnaire in cases (fragility fractures) and controls (osteoarthritis); Presence of histological features of osteoporotic bone in cases (fragility fractures) and controls (osteoarthritis); Presence of histological features of muscle atrophy in cases (fragility fractures) and controls (osteoarthritis); Myostatin serum levels in cases (fragility fractures) and controls (osteoarthritis); Insulin-like growth factor 1 (IGF-1) serum levels in cases (fragility fractures) and controls (osteoarthritis); Acceptability of the Fre...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.